Project Grant HT9425261E379
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90027, USA
Similar Awards
- Federal Grant Award Summary Children's Hospital Los Angeles received a $1.012 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), awarded on September 15, 2026, with performance extending through September 14, 2030. The award funds the development of an international multi-institutional aqueous humor biorepository designed to support biomarker studies in rare ocular cancers. This initiative involves establishing...
- This Project Grant award of $434,993 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Children's Hospital Los Angeles. The funding supports research using high-throughput sequencing of the immunoglobulin loci to develop refined risk stratification methods for pediatric B-cell acute lymphoblastic leukemia (B-ALL). The project aims to advance understanding and treatment of this pediatric cancer, with an expected completion...
- Award Summary The Defense Health Agency awarded Beckman Research Institute of the City of Hope a Project Grant totaling $1.1M under the Military Medical Research and Development program (CFDA 12.420) to develop LRRC15-targeted Chimeric Antigen Receptor (CAR) T cell therapy for osteosarcoma. The three-year award, effective June 1, 2026 through May 31, 2029, supports translational research at the Institute's Irwindale, California facility. This project represents targeted immunotherapy development...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $934,501 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2028. The award supports research focused on developing peptide-centric chimeric antigen receptor (CAR) T-cell therapies for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $4.199 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026 through August 31, 2030. The award funds the development and optimization of B7-H3 chimeric antigen receptor (CAR) T cells for pediatric and young adult patients with sarcomas and other B7-H3-positive solid tumors. This research initiative represents an...
- The University of California, Los Angeles (UCLA), through its Office of Research Administration, was awarded a $461,840 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the development of novel therapies against high-grade pediatric glioma, a type of brain cancer, through the creation of innovative multi-omic tools and bioinformatic technologies. As part of this project, UCLA is collaborating with the...
- Federal Grant Award Summary The Defense Health Agency awarded UCLA a $1.7 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) for a three-year project period (July 1, 2026–June 30, 2029). The project focuses on the functional evaluation and optimization of chimeric antigen receptor T (CAR-T) cells targeting prostate cancer through cell-cell interaction profiling using engineered nanovials. This research represents advanced biomedical science aimed at...
- Federal Grant Award Summary Children's Research Institute received a $777,659 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2028. The award supports research titled "Use of ProResolution and Restorative Pharmacology Approaches for DMD Therapy," focusing on the development of innovative therapeutic interventions for Duchenne muscular dystrophy (DMD). The...
- Grant Award Summary Cincinnati Children's Hospital Medical Center received a $750,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective April 1, 2026 through March 31, 2029. The award funds investigator-initiated research targeting epigenetic mechanisms that drive triple-negative breast cancer, a research focus aligned with the DHA's portfolio supporting medical solutions addressing Service Member...
- Federal Project Grant Award Summary Children's Research Institute received a $405,341 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2028. The award supports research utilizing pro-resolution and restorative pharmacology approaches for Duchenne muscular dystrophy (DMD) therapy development. This research initiative advances biomedical innovation in support of the Defense...